12 results on '"Mandrup-Poulsen T"'
Search Results
2. Does type II diabetes arise from a major gene defect producing insulin resistance or beta cell dysfunction?
- Author
-
Turner, R, O'Rahilly, S, Levy, J, Rudenski, A, Clark, A, Nerup, J, Mandrup-Poulsen, T, and Hokfelt, B
- Published
- 2016
3. Interleukin-1 antagonism in type 1 diabetes of recent onset: two multicentre, randomised, double-blind, placebo-controlled trials.
- Author
-
Moran A, Bundy B, Becker DJ, DiMeglio LA, Gitelman SE, Goland R, Greenbaum CJ, Herold KC, Marks JB, Raskin P, Sanda S, Schatz D, Wherrett DK, Wilson DM, Krischer JP, Skyler JS, Pickersgill L, de Koning E, Ziegler AG, Böehm B, Badenhoop K, Schloot N, Bak JF, Pozzilli P, Mauricio D, Donath MY, Castaño L, Wägner A, Lervang HH, Perrild H, and Mandrup-Poulsen T
- Subjects
- Adolescent, Adult, Analysis of Variance, Antibodies, Monoclonal, Humanized, C-Peptide drug effects, Child, Double-Blind Method, Female, Humans, Insulin-Secreting Cells drug effects, Interleukin-1 antagonists & inhibitors, Male, Treatment Outcome, Young Adult, Antibodies, Monoclonal therapeutic use, Diabetes Mellitus, Type 1 drug therapy, Hypoglycemic Agents therapeutic use, Immunologic Factors therapeutic use, Interleukin 1 Receptor Antagonist Protein therapeutic use
- Abstract
Background: Innate immunity contributes to the pathogenesis of autoimmune diseases, such as type 1 diabetes, but until now no randomised, controlled trials of blockade of the key innate immune mediator interleukin-1 have been done. We aimed to assess whether canakinumab, a human monoclonal anti-interleukin-1 antibody, or anakinra, a human interleukin-1 receptor antagonist, improved β-cell function in recent-onset type 1 diabetes., Methods: We did two randomised, placebo-controlled trials in two groups of patients with recent-onset type 1 diabetes and mixed-meal-tolerance-test-stimulated C peptide of at least 0·2 nM. Patients in the canakinumab trial were aged 6-45 years and those in the anakinra trial were aged 18-35 years. Patients in the canakinumab trial were enrolled at 12 sites in the USA and Canada and those in the anakinra trial were enrolled at 14 sites across Europe. Participants were randomly assigned by computer-generated blocked randomisation to subcutaneous injection of either 2 mg/kg (maximum 300 mg) canakinumab or placebo monthly for 12 months or 100 mg anakinra or placebo daily for 9 months. Participants and carers were masked to treatment assignment. The primary endpoint was baseline-adjusted 2-h area under curve C-peptide response to the mixed meal tolerance test at 12 months (canakinumab trial) and 9 months (anakinra trial). Analyses were by intention to treat. These studies are registered with ClinicalTrials.gov, numbers NCT00947427 and NCT00711503, and EudraCT number 2007-007146-34., Findings: Patients were enrolled in the canakinumab trial between Nov 12, 2010, and April 11, 2011, and in the anakinra trial between Jan 26, 2009, and May 25, 2011. 69 patients were randomly assigned to canakinumab (n=47) or placebo (n=22) monthly for 12 months and 69 were randomly assigned to anakinra (n=35) or placebo (n=34) daily for 9 months. No interim analyses were done. 45 canakinumab-treated and 21 placebo-treated patients in the canakinumab trial and 25 anakinra-treated and 26 placebo-treated patients in the anakinra trial were included in the primary analyses. The difference in C peptide area under curve between the canakinumab and placebo groups at 12 months was 0·01 nmol/L (95% CI -0·11 to 0·14; p=0·86), and between the anakinra and the placebo groups at 9 months was 0·02 nmol/L (-0·09 to 0·15; p=0·71). The number and severity of adverse events did not differ between groups in the canakinumab trial. In the anakinra trial, patients in the anakinra group had significantly higher grades of adverse events than the placebo group (p=0·018), which was mainly because of a higher number of injection site reactions in the anakinra group., Interpretation: Canakinumab and anakinra were safe but were not effective as single immunomodulatory drugs in recent-onset type 1 diabetes. Interleukin-1 blockade might be more effective in combination with treatments that target adaptive immunity in organ-specific autoimmune disorders., Funding: National Institutes of Health and Juvenile Diabetes Research Foundation., (Copyright © 2013 Elsevier Ltd. All rights reserved.)
- Published
- 2013
- Full Text
- View/download PDF
4. Transcriptional and translational regulation of cytokine signaling in inflammatory β-cell dysfunction and apoptosis.
- Author
-
Novotny GW, Lundh M, Backe MB, Christensen DP, Hansen JB, Dahllöf MS, Pallesen EM, and Mandrup-Poulsen T
- Subjects
- Animals, Apoptosis genetics, Apoptosis physiology, Histone Deacetylases metabolism, Humans, Inflammation Mediators metabolism, MicroRNAs genetics, MicroRNAs metabolism, Models, Biological, Protein Biosynthesis, RNA Processing, Post-Transcriptional, Reactive Oxygen Species metabolism, Signal Transduction, Transcription, Genetic, Cytokines genetics, Cytokines physiology, Insulin-Secreting Cells pathology, Insulin-Secreting Cells physiology
- Abstract
Disease is conventionally viewed as the chaotic inappropriate outcome of deranged tissue function resulting from aberrancies in cellular processes. Yet the patho-biology of cellular dysfunction and death encompasses a coordinated network no less sophisticated and regulated than maintenance of homeostatic balance. Cellular demise is far from passive subordination to stress but requires controlled coordination of energy-requiring activities including gene transcription and protein translation that determine the graded transition between defensive mechanisms, cell cycle regulation, dedifferentiation and ultimately to the activation of death programmes. In fact, most stressors stimulate both homeostasis and regeneration on one hand and impairment and destruction on the other, depending on the ambient circumstances. Here we illustrate this bimodal ambiguity in cell response by reviewing recent progress in our understanding of how the pancreatic β cell copes with inflammatory stress by changing gene transcription and protein translation by the differential and interconnected action of reactive oxygen and nitric oxide species, microRNAs and posttranslational protein modifications., (Copyright © 2012 Elsevier Inc. All rights reserved.)
- Published
- 2012
- Full Text
- View/download PDF
5. TiSH--a robust and sensitive global phosphoproteomics strategy employing a combination of TiO2, SIMAC, and HILIC.
- Author
-
Engholm-Keller K, Birck P, Størling J, Pociot F, Mandrup-Poulsen T, and Larsen MR
- Subjects
- Animals, Cell Line, Tumor, Insulinoma metabolism, Interferon-gamma pharmacology, Phosphopeptides chemistry, Phosphorylation, Rats, Sensitivity and Specificity, Signal Transduction drug effects, Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization, Chemical Fractionation methods, Chromatography, Liquid methods, Phosphopeptides isolation & purification, Proteomics methods, Titanium chemistry
- Abstract
Large scale quantitative phosphoproteomics depends upon multidimensional strategies for peptide fractionation, phosphopeptide enrichment, and mass spectrometric analysis. Previously, most robust comprehensive large-scale phosphoproteomics strategies have relied on milligram amounts of protein. We have set up a multi-dimensional phosphoproteomics strategy combining a number of well-established enrichment and fraction methods: An initial TiO(2) phosphopeptide pre-enrichment step is followed by post-fractionation using sequential elution from IMAC (SIMAC) to separate multi- and mono-phosphorylated peptides, and hydrophilic interaction liquid chromatography (HILIC) of the mono-phosphorylated peptides (collectively abbreviated "TiSH"). The advantages of the strategy include a high specificity and sample preparation workload reduction due to the TiO(2) pre-enrichment step, as well as low adsorptive losses. We demonstrate the capability of this strategy by quantitative investigation of early interferon-γ signaling in low quantities of insulinoma cells. We identified ~6600 unique phosphopeptides from 300 μg of peptides/condition (22 unique phosphopeptides/μg) in a duplex dimethyl labeling experiment, with an enrichment specificity>94%. When doing network analysis of putative phosphorylation changes it could be noted that the identified protein interaction network centered upon proteins known to be affected by the interferon-γ pathway, thereby supporting the utility of this global phosphoproteomics strategy. This strategy thus shows great potential for interrogating signaling networks from low amounts of sample with high sensitivity and specificity., (Copyright © 2012 Elsevier B.V. All rights reserved.)
- Published
- 2012
- Full Text
- View/download PDF
6. (19)F-heptuloses as tools for the non-invasive imaging of GLUT2-expressing cells.
- Author
-
Malaisse WJ, Zhang Y, Louchami K, Sharma S, Dresselaers T, Himmelreich U, Novotny GW, Mandrup-Poulsen T, Waschke D, Leshch Y, Thimm J, Thiem J, and Sener A
- Subjects
- Animals, Cell Line, Cell Survival, Female, Fluorine chemistry, In Vitro Techniques, Insulin biosynthesis, Islets of Langerhans metabolism, Magnetic Resonance Imaging, Magnetic Resonance Spectroscopy, Mannoheptulose chemistry, Mannoheptulose pharmacokinetics, Phantoms, Imaging, Rats, Rats, Wistar, Glucose Transporter Type 2 metabolism, Hepatocytes metabolism, Mannoheptulose analogs & derivatives
- Abstract
Suitable analogs of d-mannoheptulose are currently considered as possible tools for the non-invasive imaging of pancreatic islet insulin-producing cells. Here, we examined whether (19)F-heptuloses could be used for non-invasive imaging of GLUT2-expressing cells. After 20 min incubation, the uptake of (19)F-heptuloses (25 mM) by rat hepatocytes, as assessed by (19)F NMR spectroscopy, ranged from 0.50 (1-deoxy-1-fluoro-d-mannoheptulose and 3-deoxy-3-fluoro-d-mannoheptulose) to 0.25 (1,3-dideoxy-1,3-difluoro-d-mannoheptulose) and 0.13 (1-deoxy-1-fluoro-d-glucoheptulose, 3-deoxy-3-fluoro-d-glucoheptulose and 1,3-dideoxy-1,3-difluoro-d-glucoheptulose) μmol per 3×10(6)cells. (19)F MRI experiments also allowed the detection of 1-deoxy-1-fluoro-d-mannoheptulose in rat hepatocytes. All three (19)F-mannoheptuloses cited above, as well as 7-deoxy-7-fluoro-d-mannoheptulose and 1-deoxy-1-fluoro-d-glucoheptulose inhibited insulin release evoked in rat isolated pancreatic islets by 10mM d-glucose to the same extent as that observed with an equivalent concentration (10mM) of d-mannoheptulose, while 3-deoxy-3-fluoro-d-glucoheptulose and 1,3-dideoxy-1,3-difluoro-d-glucoheptulose (also 10mM) were less potent than d-mannoheptulose in inhibiting insulin release. The 1-deoxy-1-fluoro-d-mannoheptulose and 3-deoxy-3-fluoro-d-mannoheptulose only marginally affected INS-1 cell viability. These findings are compatible with the view that selected (19)F-heptuloses may represent suitable tools for the non-invasive imaging of hepatocytes and insulin-producing cells by (19)F MRI., (Copyright © 2011 Elsevier Inc. All rights reserved.)
- Published
- 2012
- Full Text
- View/download PDF
7. RX871024 reduces NO production but does not protect against pancreatic beta-cell death induced by proinflammatory cytokines.
- Author
-
Zaitseva II, Sharoyko V, Størling J, Efendic S, Guerin C, Mandrup-Poulsen T, Nicotera P, Berggren PO, and Zaitsev SV
- Subjects
- Animals, Benzofurans pharmacology, Cells, Cultured, Insulin metabolism, Insulin Secretion, Insulin-Secreting Cells metabolism, Interferon-gamma pharmacology, Interleukin-1 pharmacology, Mice, Mice, Obese, Nitric Oxide biosynthesis, Tumor Necrosis Factor-alpha pharmacology, Cell Death drug effects, Cytokines pharmacology, Imidazoles pharmacology, Indoles pharmacology, Insulin-Secreting Cells drug effects, Nitric Oxide antagonists & inhibitors
- Abstract
The imidazoline compound RX871024 reduces IL-1beta-induced NO production thereby protecting against IL-1beta-induced beta-cell apoptosis. The aim of this study was to evaluate whether imidazolines RX871024 and efaroxan protect beta-cells against death in the presence of a combination of the cytokines IL-1beta, IFNgamma, and TNFalpha. To address this issue, experiments involving different methods for detection of cell death, different concentrations of the cytokines, and a variety of conditions of preparation and culturing of ob/ob mouse islets and beta-cells have been carried out. Thoroughly performed experiments have not been able to demonstrate a protective effect of RX871024 and efaroxan on beta-cell death induced by the combination of cytokines. However, the inhibitory effect of RX871024 on NO production in ob/ob mouse islets and beta-cells was still observed in the presence of all three cytokines and correlated with the decrease in p38 MAPK phosphorylation. Conversely, efaroxan did not affect cytokine-induced NO production. Our data indicate that a combination of pro-inflammatory cytokines IL-1beta, IFNgamma, and TNFalpha, conditions modelling those that take place in type 1 diabetes, induces pancreatic beta-cell death that does not directly correlate with NO production and cannot be counteracted with imidazoline compounds.
- Published
- 2006
- Full Text
- View/download PDF
8. Prevalence of hereditary haemochromatosis in late-onset type 1 diabetes mellitus: a retrospective study.
- Author
-
Ellervik C, Mandrup-Poulsen T, Nordestgaard BG, Larsen LE, Appleyard M, Frandsen M, Petersen P, Schlichting P, Saermark T, Tybjaerg-Hansen A, and Birgens H
- Subjects
- Adult, Analysis of Variance, Denmark epidemiology, Diabetes Mellitus, Type 1 complications, Diabetes Mellitus, Type 1 epidemiology, Female, Genotype, Hemochromatosis complications, Hemochromatosis epidemiology, Humans, Liver Diseases enzymology, Male, Middle Aged, Prevalence, Retrospective Studies, Diabetes Mellitus, Type 1 genetics, Hemochromatosis genetics, Transferrin metabolism
- Abstract
Background: Although genotyping studies suggest that hereditary haemochromatosis is one of the most common genetic disorders in white people, it is still thought of as an uncommon disease. Our aim was to test the hypothesis that hereditary haemochromatosis is a disease often overlooked in patients with late-onset type 1 diabetes mellitus, a late manifestation of untreated iron overload., Methods: We did a retrospective study in which we genotyped for the C282Y and H63D mutations in the haemochromatosis gene in 716 unselected Danish patients who developed type 1 diabetes mellitus after age 30 years and 9174 controls from the general Danish population. We also screened for hereditary haemochromatosis by assessment of transferrin saturation., Findings: More patients with diabetes (n=9, relative frequency 1.26%, 95% CI 0.58-2.37) than controls (23, 0.25%, 0.16-0.38) were homozygous for C282Y (odds ratio 4.6, 2.0-10.1, p=0.0001). These patients had unrecognised signs of haemochromatosis. Transferrin saturation and ferritin concentrations ranged from 57% to 102% and 17 microg/L to 8125 microg/L, respectively. Frequency of compound heterozygosity (C282Y/H63D) did not differ between patients with diabetes (eight) and controls (131) (odds ratio 0.8, 95% CI 0.4-1.7). Positive and negative predictive values of transferrin saturation greater than 50%, in identification of C282Y homozygosity, were 0.26 and 1.00, respectively. A saturation of less than 50% therefore excluded C282Y homozygosity, whereas a saturation of more than 50% suggested C282Y homozygosity., Interpretation: Measurement of transferrin saturation followed by genetic testing could prevent liver and heart problems and improve life expectancy in patients with diabetes. Population screening before the onset of diabetes might improve the outlook of patients even further, but will be less cost effective.
- Published
- 2001
- Full Text
- View/download PDF
9. Relation between breast-feeding and incidence rates of insulin-dependent diabetes mellitus. A hypothesis.
- Author
-
Borch-Johnsen K, Joner G, Mandrup-Poulsen T, Christy M, Zachau-Christiansen B, Kastrup K, and Nerup J
- Subjects
- Adolescent, Child, Child, Preschool, Denmark, Diabetes Mellitus, Type 1 etiology, Female, Humans, Infant, Infant, Newborn, Male, Surveys and Questionnaires, Sweden, Time Factors, Breast Feeding, Diabetes Mellitus, Type 1 epidemiology
- Abstract
The variations in incidence rates of insulin-dependent diabetes mellitus (IDDM) in childhood within and between genetically very similar Scandinavian populations and the variations in incidence rates with time are difficult to explain. Epidemiological data show that the incidence of childhood IDDM may now be declining and suggest an inverse correlation between breast-feeding frequency and IDDM in childhood. Case-control data show that diabetic children were breast-fed for shorter periods of time than their healthy siblings and the population at large and that a smaller proportion of diabetic children were ever breast-fed. It is postulated that insufficient breast-feeding of genetically susceptible newborn infants may lead to beta-cell infection and IDDM later in life.
- Published
- 1984
- Full Text
- View/download PDF
10. DNA sequences flanking the insulin gene on chromosome 11 confer risk of atherosclerosis.
- Author
-
Mandrup-Poulsen T, Owerbach D, Mortensen SA, Johansen K, Meinertz H, Sørensen H, and Nerup J
- Subjects
- Adult, Aged, Arteriosclerosis epidemiology, Base Sequence, Complement C3 genetics, Diabetes Mellitus, Type 2 epidemiology, Diabetes Mellitus, Type 2 genetics, Female, Gene Frequency, Genes, Genetic Markers, Humans, Male, Middle Aged, Polymorphism, Genetic, Sex Factors, Arteriosclerosis genetics, Chromosomes, Human, 6-12 and X, DNA analysis, Insulin genetics
- Abstract
The allelic frequency of DNA restriction fragments of a large size class (U alleles) in the polymorphic region flanking the 5'-end of the human insulin gene on chromosome 11 was 2 X 5 times higher in a group of patients with extensive atherosclerosis than in subjects in whom atherosclerosis could not be demonstrated by coronary arteriography and careful clinical examination. The U alleles apparently do not confer risk of atherosclerosis through conventional risk factors such as body weight or blood pressure or levels of blood glucose, triglycerides, cholesterol, or lipoproteins.
- Published
- 1984
- Full Text
- View/download PDF
11. Disappearance and reappearance of islet cell cytoplasmic antibodies in cyclosporin-treated insulin-dependent diabetics.
- Author
-
Mandrup-Poulsen T, Nerup J, Stiller CR, Marner B, Bille G, Heinrichs D, Martell R, Dupre J, Keown PA, and Jenner MR
- Subjects
- Adolescent, Adult, C-Peptide blood, Child, Cytoplasm immunology, Diabetes Mellitus, Type 1 blood, Diabetes Mellitus, Type 1 immunology, Female, Humans, Male, Time Factors, Autoantibodies analysis, Cyclosporins therapeutic use, Diabetes Mellitus, Type 1 drug therapy, Islets of Langerhans immunology
- Abstract
In 68 newly diagnosed patients with insulin-dependent diabetes mellitus (IDDM) whose treatment included cyclosporin (CyA) the prevalence and mean titre of islet cell cytoplasmic antibodies (ICA) fell faster than they did in the 56 who received only insulin. However, in the CyA-treated patients the prevalence or titre of ICA at diagnosis did not correlate with beta-cell function as measured by glucagon-stimulated C-peptide levels; improvement and recovery of beta-cell function after 30 days of CyA therapy occurred despite the continued presence of ICA; and CyA-induced remission of IDDM (ie, glucagon stimulated plasma C-peptide levels greater than 0.6 pmol/ml) was not predicted by nor coincident with disappearance of ICA. Therefore, although CyA therapy was associated with a higher than expected frequency of remission and faster disappearance of ICA, the two observations were not temporally and may not be causally related. ICA should not be used to identify the target population for or to predict response to immunosuppressive therapy. The contribution of ICA to the pathogenesis of beta-cell destruction in IDDM needs serious re-examination.
- Published
- 1985
- Full Text
- View/download PDF
12. A genetic marker for atherosclerosis?
- Author
-
Mandrup-Poulsen T, Owerbach D, Mortensen SA, Johansen K, Meinertz H, Sørensen H, and Nerup J
- Subjects
- Aged, Alleles, Diabetes Mellitus, Type 2 complications, Humans, Insulin genetics, Arteriosclerosis genetics, Genetic Markers
- Published
- 1984
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.